Dr. Jain on the Utility of UCART22 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
January 7th 2022Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Read More
Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL
January 12th 2018Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
Read More
Dr. Jain Discusses Treatment of Richter's Transformation in CLL
May 8th 2017Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.
Read More
Dr. Jain on PD-1 Expression in Nivolumab/Ibrutinib Combination in CLL
February 24th 2017Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).
Read More
Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLL
November 26th 2014Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.
Read More
Dr. Jain on Increased Lymphocytosis Following Treatment With a B-Cell Receptor Inhibitor
November 5th 2014Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.
Read More